Intestinal Neoplasm

Altered human epidermal growth factor receptor 2 (HER2) signaling caused by genomic amplification of ERBB2 or mutations is oncogenic and has been observed in multiple cancer types. Based on the study,… (full text at CIViC)

PMID 29338072 · Ross et al., 2018 · Open in CIViC

Afatinib monotherapy was tested in patient-derived colorectal cancer (M051) mouse xenografts and gastric cancer cell-line (NCI-N87) mouse xenografts. Tumor shrinkage was observed and tumor volume was… (full text at CIViC)

PMID 26296355 · Leto et al., 2015 · Open in CIViC

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab aft… (full text at CIViC)

PMID 28223103 · Jeong et al., 2017 · Open in CIViC

141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and ch… (full text at CIViC)

PMID 24146218 · Sclafani et al., 2013 · Open in CIViC

HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients… (full text at CIViC)

PMID 23348520 · Martin et al., 2013 · Open in CIViC

In an updated report of a part of the phase 2a MyPathway trial, 57 patients with treatment-refractory, metastatic colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objecti… (full text at CIViC)

PMID 30857956 · Meric-Bernstam et al., 2019 · Open in CIViC

In this clinical study of 38 patients with colorectal cancer (CRC), 28 had CRC with ERBB2 amplification, and were treated with a combination of Pertuzumab and Trastuzumab. The DC rate in the patients … (full text at CIViC)

PMID 36315917 · Gupta et al., 2022 · Open in CIViC

In this open-label, phase II trial, 78 patients were enrolled in the study; for the 53 patients with HER2-positive tumours (cohort A), a confirmed objective response was reported in 24 patients (95% C… (full text at CIViC)

PMID 33961795 · Siena et al., 2021 · Open in CIViC

In NCI-MATCH, patients with advanced solid tumors other than breast and gastro-esophageal tumors harboring ERBB2 amplification were treated with ad-trastuzumab emtansine (T-DM1). ERBB2 amplification w… (full text at CIViC)

PMID 31504139 · Jhaveri et al., 2019 · Open in CIViC

Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 week… (full text at CIViC)

PMID 27108243 · Sartore-Bianchi et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Thirty of 1… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In an in vitro study, NCI-H508 cell lines expressing an ERBB2 L755S mutation demonstrated resistance to cetuximab treatment (IC50 > 200 ug/mL) compared with NCI-H508 cells expressing ERBB2 wild type (… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRA… (full text at CIViC)

PMID 27626067 · Aung et al., 2016 · Open in CIViC

bp] In an in vitro study, NCI-H508 cell lines expressing an ERBB2 L866M mutation demonstrated resistance to cetuximab treatment compared to NCI-H508 cells expressing ERBB2 wild-type. Resistance was de… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

In this clinical study of 38 patients with colorectal cancer (CRC), 10 had CRC with ERBB2/ERBB3 mutation, and were treated with a combination of Pertuzumab and Trastuzumab. A DC of 10% and OR of 0% we… (full text at CIViC)

PMID 36315917 · Gupta et al., 2022 · Open in CIViC

HER2 (ERBB2) overexpressing cell lines were generated by lentiviral transduction of HER2 into three colorectal carcinoma cell lines. HER2 overexpressing cell lines were found to be resistant to cetux… (full text at CIViC)

PMID 26296355 · Leto et al., 2015 · Open in CIViC

HER2 (ERBB2) overexpressing cell lines were generated by lentiviral transduction of HER2 into three colorectal carcinoma cell lines. Mouse xenografts of NCI-H508-HER2 cells were treated with single a… (full text at CIViC)

PMID 26296355 · Leto et al., 2015 · Open in CIViC

bp]In an in vitro study, NCI-H508 cell lines expressing an ERBB2 S310F mutation demonstrated resistance to cetuximab treatment, compared to NCI-H508 cells expressing ERBB2 wild-type. Resistance was de… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

In an in vitro study, NCI-H508 cell lines expressing an ERBB2 V777L mutation demonstrated resistance to cetuximab treatment (IC50 >200 ug/ml) compared to NCI-H508 cells expressing ERBB2 wild-type (IC5… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

bp]In an in vitro study, DiFi and NCI-H508 cell lines expressing an ERBB2 V842I mutation demonstrated resistance to cetuximab treatment, compared to DiFi and NCI-H508 cells expressing ERBB2 wild-type.… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC)

PMID 26243863 · Kavuri et al., 2015 · Open in CIViC

High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were availa… (full text at CIViC)

PMID 25520391 · Cushman et al., 2015 · Open in CIViC

ERCC6 was knocked down using shRNA in HCT116 and DLD1 human colorectal cancer (CRC) cell lines, which made both cell lines more sensitive to 5-FU. To assess whether ERCC6 influences chemosensitivity i… (full text at CIViC)

PMID 28665687 · Zhao et al., 2017 · Open in CIViC

226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high E… (full text at CIViC)

PMID 23374602 · Pentheroudakis et al., 2013 · Open in CIViC

Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified… (full text at CIViC)

PMID 26867820 · Seligmann et al., 2016 · Open in CIViC

The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (… (full text at CIViC)

PMID 21926398 · Crea et al., 2012 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including SNU-C2B cell line harboring FBW7 G579W mutation, were associated with resistance to rego… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including SW837 cell line harboring FBW7 L403fs*34 mutation, were associated with resistance to r… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders … (full text at CIViC)

PMID 26508446 · Lupini et al., 2015 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including LoVo cell line harboring FBW7 R505C mutation, were associated with resistance to regoraf… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including LS411N cell line harboring FBW7 R505H mutation, were associated with resistance to regor… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including HCT-8 cell line harboring FBW7 R658Q mutation, were associated with resistance to regora… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including SW48 cell line harboring FBW7 S668fs*39 mutation, were associated with resistance to re… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

Among 76 patients with refractory metastatic colorectal cancer treated with regorafenib, FGFR1 amplification was identified in three patients (3.9%), and all three achieved a partial response to regor… (full text at CIViC)

PMID 33224274 · Lee et al., 2020 · Open in CIViC

In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed … (full text at CIViC)

PMID 24135816 · Göke et al., 2013 · Open in CIViC

FGFR2 over-expression was observed in 75.9 % (n = 107)of the 141 eligible patients and was correlated with perineural invasion (P = 0.005) and inferior tumor regression grading (TRG) (P = 0.009). On u… (full text at CIViC)

PMID 26831663 · Yoon et al., 2016 · Open in CIViC

Study compares JNJ-42756493 (erdafitinib) treatment of colorectal cancer cell lines with and without FGFR2 overexpression. Overexpression determined by fold increase of FGFR2 mRNA compared to HPRT. … (full text at CIViC)

PMID 26675289 · Verstraete et al., 2015 · Open in CIViC

A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial resp… (full text at CIViC)

PMID 27906677 · Lim et al., 2017 · Open in CIViC

Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated showed significant symptomatic and laboratory improvement with so… (full text at CIViC)

PMID 25848357 · Moreira et al., 2015 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

Continuous exposure to oxaliplatin was used to produce an oxaliplatin resistant HCT116 cell line (HCT116/OXA), that showed significantly higher IC50 (145.5 ± 3.52 μM vs. 7.53 ± 0.63 μM) than the paren… (full text at CIViC)

PMID 32110058 · Chen et al., 2020 · Open in CIViC